
This article was downloaded by: [University of Bath] On: 04 October 2014, At: 10:36 Publisher: Taylor & Francis Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids Publication details, including instructions for authors and subscription information: http://www.tandfonline.com/loi/Incn20

SYNTHESIS AND ANTIVIRAL ACTIVITY OF D- AND L-2'-AZIDO-2',3'-DIDEOXY-4'-THIOPYRIMIDINE AND PURINE NUCLEOSIDES

Lak Shin Jeong ^a , Yun Ha Kim ^a , Hea Ok Kim ^b , Su Jeong Yoo ^a , Yong Hee Park ^a , Sook Hee Yeon ^a , Moon Woo Chun ^c & Hee-Doo Kim ^d

^a College of Pharmacy, Ewha Womans University, Seoul, Korea

^b College of Medicine, Yonsei University, Seoul, Korea

 $^{\rm c}$ College of Pharmacy, Seoul National University , Seoul, Korea

^d College of Pharmacy, Sookmyung Women's University, Seoul, Korea Published online: 07 Feb 2007.

To cite this article: Lak Shin Jeong , Yun Ha Kim , Hea Ok Kim , Su Jeong Yoo , Yong Hee Park , Sook Hee Yeon , Moon Woo Chun & Hee-Doo Kim (2001) SYNTHESIS AND ANTIVIRAL ACTIVITY OF D- AND L-2'-AZIDO-2',3'-DIDEOXY-4'-THIOPYRIMIDINE AND PURINE NUCLEOSIDES, Nucleosides, Nucleosides and Nucleic Acids, 20:4-7, 665-668

To link to this article: <u>http://dx.doi.org/10.1081/NCN-100002346</u>

PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms & Conditions of access and use can be found at http://www.tandfonline.com/page/terms-and-conditions

NUCLEOSIDES, NUCLEOTIDES & NUCLEIC ACIDS, 20(4-7), 665-668 (2001)

SYNTHESIS AND ANTIVIRAL ACTIVITY OF D- AND L-2'-AZIDO-2',3'-DIDEOXY-4'-THIOPYRIMIDINE AND PURINE NUCLEOSIDES

Lak Shin Jeong,^{1,*} Yun Ha Kim,¹ Hea Ok Kim,² Su Jeong Yoo,¹ Yong Hee Park,¹ Sook Hee Yeon,¹ Moon Woo Chun,³ and Hee-Doo Kim⁴

¹College of Pharmacy, Ewha Womans University, Seoul, Korea
²College of Medicine, Yonsei University, Seoul, Korea
³College of Pharmacy, Seoul National University, Seoul, Korea
⁴College of Pharmacy, Sookmyung Women's University, Seoul, Korea

ABSTRACT

Novel D- and L-2'-azido-2',3'-dideoxy-4'-thionucleosides were synthesized starting from L- and D-xylose via D- and L-4-thioarabitol derivative as key intermediates and evaluated for antiviral activity, respectively. When the final nucleosides were tested against HIV-1, HSV-1, HSV-2, and HCMV, they were found to be only active against HCMV without cytotoxicity up to 100 μ g/ml.

INTRODUCTION

Since 3'-azido-3'-deoxythymidine (AZT) has been discovered as anti-AIDS drug, a series of 2',3'-dideoxynucleosides with azido substituent at 2', 3' or 4' position of furanose moiety have been synthesized and many of them have shown potent antiviral activity (1). The 4'-thionucleosides have also shown promising biological activities such as antitumor and antiviral activities (2), but their structure-activity relationships have not been studied due to their synthetic difficulties. Recently, our laboratory developed very efficient synthetic procedure of 4-thioarabitol derivative which could be converted to the various 2'-substituted-4'-thionucleosides (3).

^{*}Corresponding author.

| ORDER | | REPRINTS |
|-------|--|----------|
|-------|--|----------|

JEONG ET AL.




Figure 1.


Utilizing this procedure, it was interesting to design and synthesize 2'azido-2',3'-dideoxy-4'-thionucleosides since the corresponding 2'-azido-2',3'dideoxynucleosides exhibited potent antiviral activity. In addition to D-nucleosides, we also wanted to synthesize the corresponding L-nucleosides because many L-nucleosides were found to be more potent than the corresponding D-nucleosides and to compare their antiviral activities.

Here, we wish to report the synthesis and antiviral activity of D- and L-2'-azido-2',3'-dideoxy-4'-thionucleosides starting from L-xylose and D-xylose, respectively.

RESULTS AND DISCUSSION

For the synthesis of the desired azido substituted nucleosides, L-2-azido-4thiosugar acetate 7 was first synthesized and then condensed with pyrimidine and purine bases. Synthesis of the key intermediate 7 is shown in Scheme 1.

D-Xylose was converted to the L-4-thioarabitol derivative 1 according to the very efficient method developed by our laboratory (2). Debenzylation (84%) of 1 with boron trichloride at -78° C gave diol 2 which was selectively silylated to give 3 in 76% yield. Barton's deoxygenation of 3 afforded deoxygenated material 4 (70%). Treatment of benzoate 4 with methanolic ammonia produced compound 5 (78%) which was converted to the azide 6 in two steps (84%). Oxidation of 6 with *m*CPBA (98%) followed by refluxing of the sulfoxide 6 with acetic anhydride gave the glycosyl donor 7.



Scheme 1.


Marcel Dekker, Inc. 270 Madison Avenue, New York, New York 10016



Copyright © Marcel Dekker, Inc. All rights reserved

| ORDER | | REPRINTS |
|-------|--|----------|
|-------|--|----------|

D- AND L-2'-AZIDO-2',3'-DIDEOXY-4'-THIONUCLEOSIDES




Scheme 2.

Synthesis of the desired pyrimidine nucleosides is depicted in Scheme 2. The glycosyl donor 7 was condensed with silvlated uracil, thymine and N^4 -benzoylcytosine in the presence of TMSOTf to give the inseparable anomeric mixture of protected nucleosides **8a/8b** (87%) and **9a/9b** (61%) and separable mixture of **10a** (30%) and **10b** (31%) after silica gel column chromatography, respectively.

Desilylation of **8a/8b** and **9a/9b** with tetra-*n*-butylammonium fluoride also afforded the inseparable mixture of the final nucleosides, respectively, which for the separation of anomers, were benzoylated at 70°C to give the O,N-dibenzoates. Dibenzoates were easily separated by silica gel column chromatography whose each anomers were treated with methanolic ammonia to yield the L-uracil derivative **11a** and **11b** and the L-thymine derivative **12a** and **12b**, respectively. The cytosine derivatives **10a** and **10b** were each deprotected to give the L-cytosine nucleosides **13a** (75%) and **13b** (70%).

Synthesis of the purine nucleosides is shown in Scheme 3. Condensation of 7 with silylated 6-chloropurine gave the inseparable mixture of protected nucleosides



Scheme 3.

667



| ORDER | | REPRINTS |
|-------|--|----------|
|-------|--|----------|

14 (71%) which was deprotected to give β -L-anomer 15a (55%) and α -L-anomer 15b (34%). Each L-anomer was converted to the L-adenine (16a, 16b), L-N⁶-methyladenine (17a, 17b), and L-hypoxanthine (18a, 18b) derivatives, respectively. The corresponding D-nucleosides (ent-11a, ent-11b, ent-12a, ent-12b, ent-13a, ent-13b, ent-15a, ent-15b, ent-16a, ent-16b, ent-17a, ent-17b, ent-18a, and ent-18b) were synthesized starting from L-xylose using the same method used in the preparation of L-nucleosides.

Antiviral assays against HIV-1, HSV-1, HSV-2, and HCMV were performed on the D- and L-final nucleosides (4). All compounds did not exhibit any significant antiviral activity except anti-HCMV activity. D-purine analogues exhibited significant anti-HCMV activity among which N^6 -methyladenine derivatives (**ent-17a** and **ent-17b**) were found to be the most potent, while L-derivatives did not show anti-HCMV activity.

ACKNOWLEDGMENTS

This research was supported by the grant of the Good Health R & D Project, Ministry of Health and Welfare, Korea (HMP-98-D-4-0057).

REFERENCES

- 1. Nasr, M.; Litterst, C.; McGowan, J. *Antiviral Res.* **1990**, *14*, 125–148 and references cited therein.
- a) Dyson, M. R.; Coe, P. L.; Walker, R. T. J. Med. Chem. 1991, 34, 2782. b) Secrist, J. A., III; Tiwari, K. N.; Riodan, J. M.; Montgomery, J. A. J. Med. Chem. 1991, 34, 2361. c) Uenishi, J.; Mototama, M.; Nishiyama, Y.; Wakabayashi, S. J. J. Chem. Soc., Chem. Commun. 1991, 1421. d) Uenishi, J.; Takahashi, K.; Motoyama, M.; Akashi, H.; Sasaki, T. Nucleosides Nuclotides 1994, 13, 1347. e) Van Draanen, N. A.; Freeman, G. A.; Short, S. A.; Harvey, R.; Jansen, R.; Szczech, G.; Koszalka, G. W. J. Med. Chem. 1996, 39, 789. f) Rahim, S. G.; Trivedi, N.; Bogunovic-Batchelor, M. V.; Hardy, G. W.; Mills, G.; Selway, J. W. T.; Snowden, W.; Littler, E.; Coe, P. L.; Basnak, I.; Whale, R. F.; Walker, R. T. J. Med. Chem. 1996, 39, 789. g) Yoshimura, Y.; Kitano, K.; Satoh, H.; Watanabe, M.; Miura, S.; Sakata, S.; Sasaki, T.; Matsuda, A. J. Org. Chem. 1996, 61, 822. h) Jeong, L. S.; Nicklaus, M. C.; George, C.; Marquez, V. E. Tetrahedron Lett. 1994, 35, 7569. i) Jeong, L. S.; Nicklaus, M. C.; George, C.; Marquez, V. E. Tetrahedron Lett. 1994, 35, 7573.
- a) Jeong, L. S.; Moon, H. R.; Choi, Y. J.; Chun, M. W.; Kim. H. O. J. Org. Chem. 1998, 63, 4821. b) Jeong, L. S.; Yoo, S. J.; Moon, H. R.; Kim, Y. H.; Chun, M. W. J. Chem. Soc., Perkin Trans 1, 1998, 20, 3325.
- 4. Neyts, J.; Snoeck, R.; Schols, D.; Himpens, B.; De Clercq, E. J. Virol. Methods. 1991, 35, 27–38.

668



Request Permission or Order Reprints Instantly!

Interested in copying and sharing this article? In most cases, U.S. Copyright Law requires that you get permission from the article's rightsholder before using copyrighted content.

All information and materials found in this article, including but not limited to text, trademarks, patents, logos, graphics and images (the "Materials"), are the copyrighted works and other forms of intellectual property of Marcel Dekker, Inc., or its licensors. All rights not expressly granted are reserved.

Get permission to lawfully reproduce and distribute the Materials or order reprints quickly and painlessly. Simply click on the "Request Permission/Reprints Here" link below and follow the instructions. Visit the <u>U.S. Copyright Office</u> for information on Fair Use limitations of U.S. copyright law. Please refer to The Association of American Publishers' (AAP) website for guidelines on <u>Fair Use in the Classroom</u>.

The Materials are for your personal use only and cannot be reformatted, reposted, resold or distributed by electronic means or otherwise without permission from Marcel Dekker, Inc. Marcel Dekker, Inc. grants you the limited right to display the Materials only on your personal computer or personal wireless device, and to copy and download single copies of such Materials provided that any copyright, trademark or other notice appearing on such Materials is also retained by, displayed, copied or downloaded as part of the Materials and is not removed or obscured, and provided you do not edit, modify, alter or enhance the Materials. Please refer to our <u>Website</u> User Agreement for more details.

Order now!

Reprints of this article can also be ordered at http://www.dekker.com/servlet/product/DOI/101081NCN100002346